Eribulin Mesylate
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Aug 1, 2010 → —
NCT ID
NCT01142661About Eribulin Mesylate
Eribulin Mesylate is a pre-clinical stage product being developed by Eisai for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01142661. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03441360 | Phase 2 | Completed |
| NCT03583944 | Approved | Completed |
| NCT03361436 | Phase 1 | Active |
| NCT03437083 | Pre-clinical | Completed |
| NCT03058406 | Pre-clinical | Completed |
| NCT02481050 | Phase 2 | Completed |
| NCT02338037 | Phase 1 | Completed |
| NCT02171260 | Phase 1 | Completed |
| NCT03245112 | Pre-clinical | UNKNOWN |
| NCT01961544 | Approved | Completed |
| NCT01458249 | Phase 2 | Completed |
| NCT01463891 | Pre-clinical | Completed |
| NCT01328249 | Phase 2 | Completed |
| NCT01240421 | Pre-clinical | Completed |
| NCT01268150 | Phase 2 | Completed |
| NCT01269346 | Phase 2 | Completed |
| NCT01142661 | Pre-clinical | Completed |
| NCT01106248 | Phase 1 | Completed |
| NCT00965523 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Cancer